Decades in the mak­ing, Ky­owa Hakko Kirin fi­nal­ly wins FDA ap­proval for add-on Parkin­son's ther­a­py

More than two decades af­ter Ky­owa Hakko Kirin kicked off the clin­i­cal eval­u­a­tion of its Parkin­son’s dis­ease drug, the Japan­ese phar­ma group has fi­nal­ly se­cured …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.